tumor effect News
-
Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting
Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the SITC Annual Meeting in National Harbor, Maryland on November 9, 2019. The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to ...
-
Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted ...
-
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers ...
By Alkermes
-
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. CTT1403 is a peptidomimetic drug that targets Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate ...
-
CD ComputaBio Announces PD-L1 Targeting Service for Anticancer Drug Research
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research. Over the past decade, ...
-
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expenses Data reported in early July 2021 from EVX-01 Phase 1/2a clinical trial showed a robust anti-tumor effect in combination with anti-PD-1 treatment for ...
-
ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), was evaluated in an open label study in seven patients with metastatic, inoperable ...
-
PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists. ...
-
Alfa Chemistry Announces the Launch of Extracted Peptides
Demonstrating competence in peptide R&D, production, and sales integration, the US-based chemical supplier Alfa Chemistry recently announced the launch of its peptide product line for researchers across the globe. After this move, a wide range of high-quality extracted peptides, including hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea ...
-
Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral ...
-
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors. Arteriovenous malformations (AVMs) occur when capillaries, veins, and ...
-
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for its lead clinical oncology program, RTX-240, for the ...
-
The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at the Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor ...
-
Study Demonstrate Superiority of VeraForm® Marker Over Clips
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO conference in Chicago and the American College of ...
-
AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy
Our AACR Presentation #1731 is now available. Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. While the advent of these inhibitors has brought significant benefit to patients with ...
By Exscientia
-
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. “We ...
By Ibio, Inc.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote address at the Advanced Therapies Congress & Expo in London, taking place October 5-6. Dr. Keirstead will speak at the following time and location: Keynote: Cell-based ...
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
IRVINE, Calif. – Nov. 16, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore-based congress is being held virtually November 17-18. Dr. Keirstead’s speaking details are as follows: Keynote: A Fully ...
-
AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you